Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- e-Trial Proposes Multinational Trials Including China
August 7, 2006
- GENERIC NEWS IN BRIEF
August 7, 2006
- MEDICAL DEVICE NEWS IN BRIEF
August 7, 2006
- Approval of 32 Products Released
August 7, 2006
- All-case Studies Increasingly a Condition for Approval: OPIR
August 7, 2006
- Council Recommends Early Approval of 4 Drugs
August 7, 2006
- Chuikyo Listens to FPMAJ, PhRMA, EFPIA on Drug Pricing
August 7, 2006
- JMA Opposed to More Frequent NHI Price Revision
August 7, 2006
- SELF-MEDICATION NEWS IN BRIEF
August 7, 2006
- REGULATORY NEWS IN BRIEF
August 7, 2006
- Santen Aims for Global Business Development in FY2006-2010 Management Plan
August 7, 2006
- DSP, BMKK Enter Agreements for Hypertension, Cancer Treatments
August 7, 2006
- Meiji Seika Licenses Non-steroidal Compounds to US Company
August 7, 2006
- 24 Products Currently in Vaccine Pipeline: GSK
August 7, 2006
- Eisai, Solvay Announce License Agreement for SA-001
August 7, 2006
- Wyeth Focuses on Developing 2nd-Generation Pneumococcal Vaccine
August 7, 2006
- New Laws Shorten "Drug Lag" in China: Mr Kosaku of CMIC
August 7, 2006
- Drug Development Beyond Borders - Today's Global Cooperative Clinical Trials -
August 7, 2006
- REGULATORY NEWS IN BRIEF
July 31, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 31, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…